Thyme Care just doubled its valuation to more than $2 billion after closing a $125 million funding round, a signal that investors still see massive upside in tech-enabled cancer care even as digital health funding remains choppy. The raise, first puts the four-year-old startup among the most richly valued oncology-focused health tech companies in the…